Shopping Cart
- Remove All
Your shopping cart is currently empty
AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. AAL993 has a weak inhibitory effect on other tyrosine kinases. AAL993 also shows potent antiangiogenic and antitumor activities.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $38 | In Stock | |
| 5 mg | $89 | In Stock | |
| 10 mg | $148 | In Stock | |
| 25 mg | $289 | In Stock | |
| 50 mg | $455 | In Stock | |
| 100 mg | $672 | In Stock | |
| 500 mg | $1,430 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock |
| Description | AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. AAL993 has a weak inhibitory effect on other tyrosine kinases. AAL993 also shows potent antiangiogenic and antitumor activities. |
| Targets&IC50 | VEGFR1:130 nM, VEGFR2:23 nM, VEGFR3:18 nM |
| In vitro | AAL993 suppressed HIF-1α expression through the inhibition of ERK without affecting Akt phosphorylation[1]. |
| In vivo | AAL993 (24-100 mg/kg; p.o.) inhibited both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases in B16 melanoma xenograft model[2]. AAL993 potently inhibited VEGF-induced angiogenesis with an ED50 value of 7 mg/kg in an implant model[2]. |
| Molecular Weight | 371.36 |
| Formula | C20H16F3N3O |
| Cas No. | 269390-77-4 |
| Smiles | FC(F)(F)c1cccc(NC(=O)c2ccccc2NCc2ccncc2)c1 |
| Relative Density. | 1.349 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (148.1 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.